SynthesisJAMA oncology2018

Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.

Georgia Ritchie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.